In addition, FGF18 + Itgβ1 may be potentially utilized for treating early detected small AAA in humans; however, further studies are needed to verify the therapeutic effects in animal species that are more easily compared to humans, such as pigs. Here, FGF18 is linked to triple-A syndrome.